15 unknown. 15 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Unknown 15 |
| Phase 1 | 4 | Unknown 4 |
Follow Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Myeloid Leukemia trials Research Report on Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KRT-232 and TKI Study in Chronic Myeloid Leukemia KRT-232, Dasatinib, Nilotinib - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Kartos Therapeutics, Inc. | 109 | 2021-05-07 | 2022-03-21 |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) Imatinib, Nilotinib, Dasatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission | Phase 2 | Unknown | National Research Center for Hematology, Russia | 100 | 2020-01-15 | 2020-10-08 |
| Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia Ponatinib - Chronic Myeloid Leukemia | Phase 2 | Unknown | Fundación Teófilo Hernando, Spain | 40 | 2019-04-30 | 2019-08-02 |
| Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia Chronic Myeloid Leukemia + NK cell - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Hospital de Clinicas de Porto Alegre | 5 | 2019-03-01 | 2019-03-12 |
| The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia Imatinib Mesylate - Chronic Myeloid Leukemia, Philadelphia Chromosome Positive CML | Phase 2 | Unknown | The University of Hong Kong | 15 | 2017-08-01 | 2017-08-08 |
| KISS Study: Kinase Inhibition With Sprycel Start up Dasatinib, Imatinib - Chronic Myeloid Leukemia | Phase 2 | Unknown | University of Auckland, New Zealand | 91 | 2017-07-17 | 2023-11-29 |
| Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene PF-114 - Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 1 / Phase 2 | Unknown | Fusion Pharma LLC | 65 | 2016-07-01 | 2020-02-17 |
| Radotinib as 3rd or Later Line Therapy in CP-CML Radotinib - Chronic Myeloid Leukemia | Phase 2 | Unknown | Ulsan University Hospital | 73 | 2015-04-01 | 2016-05-11 |
| Treatment-free Remission Accomplished With Dasatinib in Patients With CML Dasatinib - Chronic Myeloid Leukemia | Phase 2 | Unknown | University Health Network, Toronto | 131 | 2014-10-01 | 2019-11-29 |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination allogeneic donor derived B-lymphocytes - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | University of Erlangen-Nürnberg Medical School | 15 | 2013-11-01 | 2014-03-26 |
| Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Dasatinib - Chronic Myeloid Leukemia | Phase 2 | Unknown | PETHEMA Foundation | 18 | 2013-03-01 | 2015-09-17 |
| Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial Dasatinib - Chronic Myeloid Leukemia | Phase 2 | Unknown | Shimousa Hematology Study Group | 50 | 2012-02-01 | 2012-06-25 |
| Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation Cord Blood Transplant - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Colorado Blood Cancer Institute | 20 | 2005-11-01 | 2006-06-26 |
| Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Treosulfan IV - Leukemia, Chronic Myeloid Leukemia | Phase 2 | Unknown | IRCCS San Raffaele | 175 | 2005-09-01 | 2009-08-11 |
| AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year Imatinib mesylate 600mg/day, Peg-Interféron at 90 microg/week - Chronic Myeloid Leukemia | Phase 2 | Unknown | Hospices Civils de Lyon | 30 | 2004-03-01 | 2007-04-27 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (15) · Myelodysplastic Syndromes (3) · Hodgkin Disease (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Aplastic (1) · Bronchiolitis Obliterans Syndrome (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma, Large B-Cell, Diffuse (1)
Bone Marrow Diseases (15) · Chronic Disease (15) · Disease Attributes (15) · Hematologic Diseases (15) · Hemic and Lymphatic Diseases (15) · Leukemia, Myeloid (15) · Myeloproliferative Disorders (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Leukemia (13) · Immune System Diseases (4) · Immunoproliferative Disorders (3) · Leukemia, Lymphoid (3)
Dasatinib (6) · Imatinib Mesylate (4) · nilotinib (2) · 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide (1) · PF-114 (1) · bosutinib (1) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1) · ponatinib (1)
Colorado Blood Cancer Institute (1) · Fundación Teófilo Hernando, Spain (1) · Fusion Pharma LLC (1) · Hospices Civils de Lyon (1) · Hospital de Clinicas de Porto Alegre (1) · IRCCS San Raffaele (1) · Kartos Therapeutics, Inc. (1) · National Research Center for Hematology, Russia (1) · PETHEMA Foundation (1) · Shimousa Hematology Study Group (1) · The University of Hong Kong (1) · Ulsan University Hospital (1) · University Health Network, Toronto (1) · University of Auckland, New Zealand (1) · University of Erlangen-Nürnberg Medical School (1)
Russia (3) · Spain (3) · Canada (2) · France (2) · Italy (2) · South Korea (2) · United States (2) · Brazil (1) · Germany (1) · Hong Kong (1) · Japan (1) · New Zealand (1) · Poland (1)
Anna Turkina, Professor (2) · Antonio Jimenez, Dr. (1) · Blanca Xicoy, Dr. (1) · Carol Cheung, MBBS (1) · Dennis Kim, MD (1) · Fabio FC Ciceri, MD (1) · Fermin Sanchez-Guijo, MD PhD (1) · Guillermo Orti, Dr. (1) · Hawk Kim, M.D., Ph.D. (1) · Juan Carlos Hernandez, Dr. (1) · Juan Luis Steegmann, MD PhD (1) · Julia Winkler, MD (1) · Koiti Inokuchi (1) · Lucia Silla, Physician (1)
PMID 11756187, PMID 20965785, PMID 23440689, PMID 23704092, PMID 24166905, PMID 24323036, PMID 25394714, PMID 26178642, PMID 26686407, PMID 28218239, PMID 32614159, PMID 34568066, PMID 38467031, PMID 40298994
2005 (1), 2017 (1)